Roivant Sciences reported a first quarter net loss of $0.26 per share, narrower than analyst expectations, on revenue of $1.4 million which missed estimates. The company ended the quarter with a strong cash position and confirmed the receipt of a significant patent settlement payment after the period closed.
Key Highlights
- Net loss per share was $0.26, beating the consensus estimate for a loss of $0.45.
- The company held consolidated cash, cash equivalents, and marketable securities of $3.9 billion as of June 30, 2026, which does not include the $950 million patent settlement payment received from Moderna in July.
- During the quarter, Roivant repurchased 7.3 million of its common shares for approximately $208.7 million.
- The commercial launch of brepocitinib for dermatomyositis remains on track for September 2026, with several other key clinical data readouts expected in the second half of the calendar year.